July 2026 Research Update

Across these papers, a common message is that some forms of congenital adrenal hyperplasia (CAH) can be overlooked for years because signs vary by age and subtype, and because testing choices matter. In children, careful timing during a stimulation test and using baseline blood markers helped avoid missed nonclassical CAH due to 21-hydroxylase deficiency. In a smaller pediatric series of a different subtype, combining detailed hormone testing with genetic testing helped explain delayed diagnosis, hypertension, and one long-term misdiagnosis. [1] [2]

In 150 children evaluated for suspected nonclassical CAH due to 21-hydroxylase deficiency, the 60-minute 17-hydroxyprogesterone blood level during a standard stimulation test identified all diagnostic cases, while a 30-minute level alone would have missed some. Three children had normal 30-minute results but diagnostic 60-minute results, and no child was diagnosed at 30 minutes if the 60-minute result was not diagnostic. The study also reported that a baseline 17-hydroxyprogesterone cutoff of 3.78 ng/mL had 89.7% sensitivity and 94.2% specificity in this setting, and the V281L genetic change was the most common disease-causing variant found. [1]

A case series of five children with 11-beta-hydroxylase deficiency (a different CAH subtype) reported a median diagnostic delay of 2 years and highlighted how hormone patterns and genetic testing can clarify the diagnosis, including identifying two previously unreported genetic variants. One person was treated for many years as if they had 21-hydroxylase deficiency, and was only correctly diagnosed later after genetic testing. The authors also described that high blood pressure did not consistently improve with hydrocortisone alone and that four boys developed central precocious puberty after starting glucocorticoid treatment, showing how presentations can be complex even after the diagnosis is made. [2]

In two elderly men with undiagnosed nonclassical 21-hydroxylase deficiency who were found to have adrenal incidentalomas (adrenal masses found by chance), the adrenal appearance differed, with one having a large one-sided tumor and the other having both adrenals enlarged. In one man, reduced adrenal function became apparent after adrenal surgery, and both men had short stature. The authors suggested that, in older patients with incidental adrenal findings, looking for low adrenal function as well as hormone overproduction may help uncover previously unrecognized CAH. [3]

In a retrospective study of 49 genetically confirmed CAH patients with 78 paired measurements, steroid hormone results were broadly similar whether measured by immunoassay or by LC-MS/MS (a mass-spectrometry method), with all tested hormones showing correlation between methods. Among several hormones examined, only androstenedione significantly differed between patients judged clinically well controlled versus poorly controlled, suggesting it may be a more sensitive marker of day-to-day clinical control in this dataset. This study focused on monitoring rather than initial diagnosis, but it adds context on how lab methods compare when following people with confirmed CAH. [4]

For patients and caregivers, these studies mainly provide background on why CAH may be diagnosed late or labeled as a different subtype, especially when symptoms are mild, appear later in life, or overlap with other conditions. The strongest takeaways here are about testing details (for example, which time point during a stimulation test captures more cases in children) and about the value of combining hormone patterns with genetic testing when the picture does not fit. What remains uncertain is how well these lessons apply across different clinics and age groups, because some evidence comes from small case series, including single-center experiences and a two-person report in older adults. [1] [2] [3] [4]

Across this group of studies, steroid treatment and monitoring came up in three practical situations: switching to a modified-release hydrocortisone in children, managing rare 17alpha-hydroxylase deficiency with high blood pressure and low potassium, and interpreting changes during acute illness. The overall message was that lab markers and body changes (growth, bone maturation, blood pressure, adrenal size) can shift after changes in steroid exposure or during stress, and short-term improvements do not answer long-term questions. [5] [6] [7]

In a small, single-center retrospective study of 36 children and adolescents with classic 21-hydroxylase deficiency, switching from immediate-release hydrocortisone to modified-release hydrocortisone capsules lowered morning salivary hormone markers, while evening values were not clearly different. Over follow-up, growth velocity slowed and bone age moved closer to chronological age, and no adrenal crises were observed. [5]

Two case reports focused on 17alpha-hydroxylase deficiency, a rare form of congenital adrenal hyperplasia that can present with high blood pressure and low potassium along with differences in sexual development. In two unrelated teens, glucocorticoid replacement (especially dexamethasone in this report) was followed by rapid stabilization of blood pressure and potassium during follow-up, while multidisciplinary care was emphasized because of diagnostic and management complexity. [6]

A separate single-patient report in 17alpha-hydroxylase deficiency added lab-based evidence that a specific CYP17A1 frameshift mutation produced a shortened protein with complete loss of enzyme activity, matching the person's hormonal and imaging picture. This helps explain why glucocorticoid replacement is needed in this condition, but it does not by itself show which approach works best for most patients. [8]

In one adult man with 21-hydroxylase deficiency, an acute infection was linked to marked but temporary enlargement of pre-existing adrenal hyperplasia on imaging, with a large decrease in adrenal volume within one month as the stress resolved. The report also described shifting stress-related hormone patterns over time, with hydrocortisone therapy started later after follow-up labs changed. Because this is a single case, it mainly highlights that illness and recovery can complicate how scans and lab results are interpreted. [7]

For patients and caregivers, these papers mainly reinforce that monitoring in congenital adrenal hyperplasia can involve more than a single blood test, because hormone markers, growth and bone maturation (in children), blood pressure and electrolytes (especially in 17alpha-hydroxylase deficiency), and even adrenal imaging (during illness) may change with steroid exposure and with stress. Some results come from small observational studies and single-patient reports, so they are useful for understanding patterns but leave uncertainty about long-term outcomes and how broadly the results apply to different ages and genetic types. [5] [6] [8] [7]

One multicenter retrospective cohort looked at people with 21-hydroxylase deficiency who survived for long periods without glucocorticoid treatment, including classic salt-wasting, classic simple-virilizing, and non-classic forms. Overall, the study described wide variation in whether and when adrenal crises occurred during untreated years, with most crises happening in early childhood. [9]

Among classic cases, the untreated period lasted a median of 8.7 years, and nearly half of classic patients never received glucocorticoids. Among the classic patients who had never received glucocorticoids, 71% did not experience an adrenal crisis during the untreated period, based on the records available for this study. [9]

Among non-classic cases, the untreated period lasted a median of 28.1 years, and 21% were never treated. Two non-classic patients experienced an adrenal crisis, and both had the same reported genotype (I2 splice/P31L), suggesting that risk may differ within the non-classic group. [9]

This study is mainly background information about the range of real-world experiences before or without glucocorticoid treatment, rather than a guide to care. Because it was retrospective and did not compare treated versus untreated groups side-by-side, it cannot tell which approach is safer or better, but it does underline that adrenal crisis risk is not identical for every person with 21-hydroxylase deficiency and may relate to age and genetic subtype. [9]

Across these reports, reproductive outcomes in congenital adrenal hyperplasia (CAH) varied by subtype and by how well adrenal hormone levels were controlled. In classic CAH, switching the timing and release of steroid replacement was linked to more regular menstrual cycles and several pregnancies. In 17 alpha hydroxylase deficiency (17OHD), pregnancies were mostly achieved through assisted reproduction, and pregnancy complications were common, highlighting the need for coordinated endocrine and obstetric care. [10] [11]

In a small case series of eight women with classic CAH, changing from conventional glucocorticoids to modified-release hydrocortisone was followed by lower morning levels of several hormone markers and restoration of regular menstrual cycles in all participants. Five of eight conceived within a median of about 10 months, resulting in six live births and one early miscarriage, with two pregnancies described as unintended. Because this was a small, uncontrolled series, it cannot show how often these outcomes would happen in larger or different groups. [10]

In a single-center retrospective cohort combined with published case reports, 20 women with 17OHD had 20 reported pregnancies leading to 23 live births, most conceived using frozen embryo transfer after hormone suppression approaches that included glucocorticoids before embryo transfer in most cases with available data. Among pregnancies with complication information, nearly half had reported pregnancy complications, including hypertensive disorders and other serious events, and some births were preterm or by cesarean. Limited follow-up described normal development to at least age 1 year in five children, but long-term outcomes were not consistently reported. [11]

A separate case report in two siblings with 17 alpha hydroxylase/17,20-lyase deficiency due to a CYP17A1 gene variant focused on diagnosis and long-term planning rather than pregnancy outcomes. It described early hormonal testing, imaging, and multidisciplinary decisions about gonad removal and pubertal induction, underscoring that reproductive counseling and psychosocial support can be central parts of care in these conditions. As a two-patient report, it may not apply broadly. [12]

For patients and caregivers, this body of evidence mainly provides background on what has been reported in small groups rather than definitive expectations. It suggests that in classic CAH, approaches that better match the body's daily cortisol rhythm may help normalize menstrual cycles and may coincide with pregnancies, while in 17OHD, pregnancy often relies on assisted reproduction and may carry higher risks of complications that require close monitoring. Important uncertainties remain, including how results vary across individuals, which specific hormone targets best predict reproductive outcomes, and what longer-term child outcomes look like after pregnancies in these rare CAH subtypes. [10] [11] [12]

Across these papers, genital surgery is described from two angles: technical surgical goals for genital appearance and function, and the emotional and quality-of-life impact on families. Short-term surgical outcomes can look reassuring in an individual case, but family stress and anxiety were common in a broader parent survey, especially when surgery had occurred. Longer-term outcomes, including into adolescence and adulthood, were not directly addressed by the surgical case report and remain uncertain.

A cross-sectional survey of 44 parents of children under 13 with differences of sex development (most commonly congenital adrenal hyperplasia) reported that anxiety and depression were frequent, and quality of life was lower in several areas. Parents of children who had undergone genital surgery reported significantly lower quality of life across physical, emotional, social, and self-related domains, and genital surgery and family income were statistically linked with lower quality of life and anxiety. [13]

One case report described a 6-year-old girl with classic congenital adrenal hyperplasia (Prader stage 3 virilization) who had nerve-sparing ventral clitoroplasty designed to protect key structures related to blood flow and sensation. At 6 months, the report described highly satisfactory cosmetic and functional results, with preserved clitoral sensation noted at 3 months and no major early complications. The authors noted that long-term function into sexual maturity was not yet known. [14]

A separate guideline-focused article on adolescents with differences of sex development emphasized that care planning needs to address both physical aspects (including evaluation of genital variations) and psychosocial support, especially as patients transition to adult care. It highlighted common barriers such as limited acceptance of the diagnosis, lack of structured resources, and limited expertise in adult services, and supported individualized transition plans with clear medical summaries and education. [15]

For patients and caregivers, these studies together suggest that decisions and experiences around genital surgery can affect more than anatomy, and may coincide with higher stress for parents and caregivers. The strongest data here about family experience comes from a single-time-point survey, which cannot show cause and effect, while the surgical report reflects one childs short follow-up and cannot predict adolescent or adult outcomes. The transition guidance mainly serves as background: it underscores that ongoing support, clear information-sharing, and attention to emotional wellbeing are important over time, including when moving from pediatric to adult healthcare.

Across this group of studies, day-to-day wellbeing stood out more consistently than physical limitations: children, teens, and adults with congenital adrenal hyperplasia (CAH) reported lower emotional and social wellbeing than comparison groups. In contrast, brain imaging and cognitive research suggested subtle differences in brain structure and some thinking skills, but results were mixed and did not consistently link to real-world memory performance. [16] [17] [18] [19]

In a cross-sectional study of 40 children and adolescents with CAH, overall health-related quality of life was lower than in 82 healthy controls, mainly in emotional, social, and school-related areas, while physical functioning was similar. Quality of life did not show a consistent relationship with steroid dose or lab markers in this snapshot, suggesting that psychosocial experiences may be a separate part of the burden for some families. [16]

In a retrospective follow-up study of 75 adults with CAH due to 21-hydroxylase deficiency, social wellbeing differences were already visible during school age, with lower scores in more severe forms and lower scores in females than males and healthy female controls. Adult quality of life scores tracked with the average wellbeing reported across earlier life periods, suggesting that earlier social wellbeing and later adult quality of life may be linked, at least for some people. [17]

A cohort study using brain scans compared 29 people with CAH to 33 controls and found sex-specific differences in parts of the hippocampus, a region involved in learning and memory, including smaller volumes in some subfields and higher tissue diffusivity in males in certain areas. However, these structural differences were not connected to memory test performance in this study, meaning the scan differences did not clearly explain everyday memory ability. [18]

A systematic review and Bayesian meta-analysis of 11 studies focused on females with CAH and the possible effects of prenatal androgen exposure on thinking skills that often show female advantages. It reported worse verbal fluency on average, similar or slightly better spatial task performance, modestly lower perceptual speed, and mixed or uncertain results for emotion recognition and episodic memory; the authors noted that the number of studies and effect sizes were modest, limiting certainty. [19]

For patients and caregivers, this set of studies suggests that emotional, social, and school or work experiences can be a meaningful part of living with CAH, sometimes more noticeable than physical functioning measures. Brain and cognition research is mainly background context right now: it points to possible small differences on scans or specific tasks in some groups, but it does not yet give a clear picture of who will have day-to-day thinking or memory difficulties. Important uncertainties include how these patterns change over time, how strongly they relate to real-life functioning, and whether results differ by sex, severity, and life stage across larger, more diverse groups. [16] [17] [18] [19]

Across these papers, body complications in congenital adrenal hyperplasia (CAH) included tumors in hormone-sensitive tissues (testes or adrenal glands) and changes in bone-related development and blood markers. The overall direction suggests that higher long-term hormone stimulation may relate to tumor risk and may also relate to bone biology signals, but the studies were small and cannot prove cause and effect. [20] [21] [22]

In a retrospective cohort of 38 males with CAH, testicular adrenal rest tumors (TARTs) were seen on ultrasound in 14 patients (36.8%). TARTs were more likely in patients who were pubertal and in those whose bone age was more advanced than expected for their calendar age, and both factors remained linked to TARTs in the study's adjusted analysis. [20]

One case report described a 59-year-old woman with untreated classic CAH who developed very large tumors in both adrenal glands called myelolipomas (fat-containing benign tumors). After open removal of both adrenal glands, her high androgen levels resolved and symptoms such as extra hair growth and scalp hair loss improved; this is a single-person report and may not apply to others. [21]

In a cross-sectional study of 31 children with CAH treated with glucocorticoids for at least 5 years, bone mineral density scores were often in a similar range to controls, with 80% of both groups having scores above -1. However, children with CAH had higher blood levels of osteoprotegerin, and they did not show the typical puberty-related drop in sclerostin seen in healthy controls; the CAH hormone marker 17-hydroxyprogesterone was linked to both bone markers in opposite directions. [22]

For patients and caregivers, this set of studies mainly adds context about what complications have been reported and which features tracked together in small groups. The TART study suggests that puberty and faster-than-expected bone maturation went along with higher chances of TARTs on ultrasound, while the case report shows that very large adrenal myelolipomas can occur in long-untreated CAH but does not indicate how common this is. The bone marker study suggests that even when bone density looks similar to peers, blood markers of bone activity can differ in CAH, and it remains unclear how well these markers predict future bone health. [20] [21] [22]

Across these papers, genetics was used to explain why people can have similar-looking hormone-related symptoms for different reasons. In adult women with a hormone and metabolism-related ovarian condition, certain variants in adrenal steroid genes lined up with differences in hormone signals and hair-growth scores, suggesting gene differences may shape androgen exposure. In a single newborn, severe cortisol deficiency with very high ACTH looked like a steroid problem at first, but genetic testing supported a different diagnosis than congenital adrenal hyperplasia (CAH), even though the CAH newborn screen was normal. [23] [24]

In a case-control genetic association study of 110 affected premenopausal women and 165 controls, variants in CYP21A2 and CYP11B1 were tied to differences in ACTH (a hormone that stimulates the adrenal glands), sex hormone-binding globulin (a blood protein that affects how much androgen is available to tissues), body mass index, and a hair-growth scoring system. Some CYP21A2 variants linked to non-classic CAH were associated with higher ACTH, lower sex hormone-binding globulin, and higher hair-growth scores, while other combined variants were linked to lower ACTH. The study also reported that certain CYP11B1 genotypes were linked to lower sex hormone-binding globulin or lower hair-growth scores, showing that more than one adrenal-related gene may influence androgen-related traits. [23]

A separate case report described one term male newborn with striking scrotal hyperpigmentation and a normal CAH newborn screen, but blood tests showed profoundly low cortisol with markedly elevated ACTH. The infant had transient high potassium with low-normal aldosterone that needed brief mineralocorticoid support, and then remained stable with normal development and gradual lightening of the pigmentation on ongoing hormone replacement. Genetic testing found a homozygous MRAP in-frame deletion (c.88_90del; p.K30del), supporting familial glucocorticoid deficiency type 2, a condition that can mimic some early features that families might associate with CAH but has a different genetic cause. [24]

For people living with CAH, these reports mainly add background context about why hormone patterns and androgen-related signs can vary and why different conditions can overlap in outward appearance. The adult genetics study suggests that certain gene variants can shift hormone signals and androgen availability, but it does not prove cause-and-effect or tell how often these variants matter in routine care. The newborn report is a reminder that a normal CAH newborn screen does not rule out other rare adrenal hormone disorders, and that genetic testing can sometimes clarify the cause, but it is based on a single patient and may not apply broadly.